-+ 0.00%
-+ 0.00%
-+ 0.00%

Labcorp Announces Availability of Roche's Ventana Pten RxDx Assay, First Immunohistochemistry Companion Diagnostic Test Approved By FDA To Determine Pten Protein Loss In Prostate Adenocarcinoma Patients

Benzinga·08/04/2026 11:13:04
Listen to the news

The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone.